Picture of Revelation Biosciences logo

REVB Revelation Biosciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-15.46%
3m-39.09%
6m-65.32%
1yr-97.32%
Volume Change (%)
10d/3m-90.34%
Price vs... (%)
52w High-96.99%
50d MA-8.09%
200d MA-55.18%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-319.64%
Return on Equity-270.02%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Revelation Biosciences EPS forecast chart

Profile Summary

Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    September 30th, 2024
    Incorporated
    November 20th, 2019
    Public Since
    October 8th, 2020
    No. of Shareholders
    66
    No. of Employees
    9
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    4,292,455

    REVB Share Price Performance

    Upcoming Events for REVB

    Q4 2024 Revelation Biosciences Inc Earnings Release

    Q1 2025 Revelation Biosciences Inc Earnings Release

    Revelation Biosciences Inc Annual Shareholders Meeting

    Similar to REVB

    Picture of Abeona Therapeutics logo

    Abeona Therapeutics

    us flag iconNASDAQ Capital Market

    Picture of ABVC Biopharma logo

    ABVC Biopharma

    us flag iconNASDAQ Capital Market

    Picture of Acesis Holdings logo

    Acesis Holdings

    us flag iconNASDAQ Capital Market

    Picture of Achieve Life Sciences logo

    Achieve Life Sciences

    us flag iconNASDAQ Capital Market

    Picture of Achilles Therapeutics logo

    Achilles Therapeutics

    us flag iconNASDAQ Capital Market

    FAQ